



## PRESERVATION MATTERS — A.L.W.A.Y.S.

Hypogastric artery preservation is the recommended treatment<sup>1,2</sup> to sustain quality of life. When determining which preservation method is best, **A. L. W. A. Y. S.**<sup>3,4</sup> consider each patient's:

- A** Activity level
- L** Length
- W** Width
- A** Aortic Disease
- Y** Young
- S** Seal



*Pre-treatment and five-year follow-up; first clinical use.  
Images courtesy of Brian Peterson, MD. St. Anthony's  
Medical Center; St. Louis, Missouri.*

# Durable Outcomes. Proven Performance.

The GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) is the first and only off-the-shelf aortic branch solution approved in the US and is fully designed to preserve blood flow to external and internal iliac arteries.

## Global Registry for Endovascular Aortic Treatment (GREAT) IBE data

Length of follow-up (at)	2 years
Number of patients possible	68
EIA patency*	97.1%
IIA patency*	100%
Freedom from device related reintervention	92.6%
Buttock claudication	None reported
Sexual dysfunction	None reported



GORE® EXCLUDER®  
Iliac Branch Endoprosthesis

The GORE® EXCLUDER® AAA device is the most-studied† EVAR stent graft and designed for durable outcomes.

## GORE® EXCLUDER® AAA Device data from GREAT

Length of follow-up (through‡)	5 years
Number of patients possible	3,274
Type 1b endoleaks	0.7%
Limb occlusion	0.7%



GORE® EXCLUDER®  
AAA Endoprosthesis

\* Based on reported occlusion adverse events.


† Based on company-sponsored trials and registries shown on [clinicaltrials.gov](https://clinicaltrials.gov) for currently available stent grafts.

‡ GREAT. n = 3,274. To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events. Therefore, all reported endoleaks are defined as serious and require reintervention.

## References

1. Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. *Journal of Vascular Surgery* 2018;67(1):2-77.e2.
2. Moll FL, Powell JT, Fraedrich G, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European Society for Vascular Surgery. *European Journal of Vascular & Endovascular Surgery* 2011;41(Supplement 1):S1-S58.
3. Million A, Milner R, Oderich GS, Schneider DB, Spark I, Verzini F. Expert discussion: when to preserve the hypogastric artery. *Endovascular Today* 2017;16(8)Supplement:6-11.
4. Schneider DB, Milner R, Heyligers JMM, Chakfé N, Matsumura J. Outcomes of the GORE Iliac Branch Endoprosthesis in clinical trial and real-world registry settings. *Journal of Vascular Surgery* 2019;69(2):367-377.e1.

 Consult Instructions  
for Use  
[eifu.goremedical.com](https://eifu.goremedical.com)

Refer to *Instructions for Use* at [eifu.goremedical.com](https://eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available.  Only  
Products listed may not be available in all markets.

GORE, *Together, improving life*, EXCLUDER and designs are trademarks of W. L. Gore & Associates.  
© 2020 W. L. Gore & Associates, Inc. AZ0895-EN1 MAY 2020

W. L. Gore & Associates, Inc.  
[goremedical.com](https://goremedical.com)

Asia Pacific +65 67332882 Australia / New Zealand 1800 680 680 424 Europe 00800 6334 4673  
United States Flagstaff, AZ 86003 800 437 8181 928 779 2771

